• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A cephalosporin derivative of the formula:- in which R1 is any one of the C-3 substituents from antibacterially-active cephalosporins known in the art R2 is any one of the C-4 substituents from antibactenally-active cephalosporins known in the art; R3 is hydrogen, hydroxy, amino, C1-6alkyl, C1-6alkanoyl. C1-6alkoxy, C1-6alkonoylammo or C1-6alkylamino, phenylalkyl in which the alkyl part is C1-6 or phenyl in the latter two of which the phenyl is optionally substituted by methoxy: A< is a radical of the formula:- in which R4 and R5, which may be the same or different are hydrogen, halogen, cyano. hydroxy, carboxy, pyndyl, C1-6salkyl, C1-6aminoalkyl, C1-6shydroxyalkyl, C2-6alkoxycarbonyl, C2-10lkylaminoalkyl, C3-15dialkylaminoalkyl, or phenyl optionally substitued by 1 or 2 radicals selected from halogen, nitro, amino, hydroxy, carboxy, cyano, C1-6fialkyl and C2-6alkoxycarbonyl; or R4 and R5 are joined to form a mono-, bl- or tricyclic carbocyclic ring system which may be non-aromatic, partially aromatic or fully aromatic, the aromatic part being option- . ally substituted by 1.2 or 3 radicals selected from halogen, hydroxy, amino, cyano, carboxy, carbamoyl, nitro, ureido, C1-6alkyl. C1-6salkoxy, C1-6haloalkyl, C1-6alkylamino, C1-6hydroxyalkyl, C1-6saminoalkyl, C1-6alkanoylamino and C1-6azidoalkyl, C2-8 dialkylammo, C2-10alkylaminoalkyl, C3-15dialkylaminoalkyl. C2-6cyanoalkyl, C2-6carboxyalkyl, C2-6carbamoylalkyl, and C2-6ureidoalkyl and radicals of the formula:- in which n is 0 to 6, m is 4 to 8 and R10, R11. R12 and R13. which may be the same or different. are hydrogen or C1-6alkyl; and R6, R7. R8 and R9, which may be the same or different. are hydrogen, carboxy. cyano, pyridyl. CX1-6alkanoyl, C1-6hydroxyalkyl, C1-10alkyl, phenoxyalkyl radicals in which the alkyl part is C1-6 and the phenyl is optionally substitued by diphenylmethyl, or phenyls which are optionally substituted by 1. 2 or 3 radicals selected from halogen, cyano. amino. carboxy. carbamoyl. hydroxy, phenyl, phenoxy. diphenylmethyl. C1-6alkylamino, C1-6alkanoylamino. C1-6alkanesulphonylamino, C1-6aminoalkyl, C1-6hydroxyalkyl. C2-10dialkylamino. C2-6alkoxycarbonyl. C2-6alkylcarbamoyl and C3-10dialkylcarbomoyl: or R7 and R8 when in the cis relationship. are joined to form a 3 to 6 membered carbocyclic ring. the ring being optionally substituted by 1 or 2 radicals selected from phenyl and C1-6haloalkyl and the 4 to 6 membered rings optionally containing a double bond in a position other than at the ring fusion; provided that when one of R6, R7, R8 and R9 is a carboxy radical the remaining members of R6, R7. RB and R9 are hydrogen atoms: ant the pharmaceutically-acceptable acid- or base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.
    公开号:SU1077573A3
    申请号:SU813274748
    申请日:1981-04-24
    公开日:1984-02-29
    发明作者:Анри Жюнг Фредерик
    申请人:Иси Фарма (Фирма)；
    IPC主号:
    专利说明:

    A is a radical of the formula
    I
    or
    R- K JJ9
    where R and R are the same or different - hydrogen or cyano ,. hydroxy, carboxymethyl, hydroxymethyl ,. The 3-hydroxypropyl, ethoxycarbonyl, phenyl, aminomethyl, 2-hydroxypropyl, propyl, butyl or 3-aminopropyl radical, or B and R together with the carbon with which they are bonded, form a cyclohexene, benzene, naphthalene or dihydroadenaphthalene cyclic system, and benzene is optionally substituted by one or two radicals selected from the group including fluorine, chlorine, oxy, amino, carboxy, nitro, methyl, methoxy, trifluoromethyl, oxymethyl,. aminomethyl, acetylamino, azidomethyl, acetylaminomethyl, cyanomethyl, carbamoylmethyl radical and the radical of formulas
    -OCONH,
    (sn,)
    -SP NHCOCIl NH, -CH NHCOCH (
    NH.
    RR is the same or different hydrogen, hydroxymethyl, amino-methyl, carbamoyl, methoxycarbonyl, methyl, n-hexyl, phenoxymethyl, which NromeT can be substituted by diphenylmethyl or phenyl, which can be replaced by one or two radicals selected from the group that includes fluorine, chlorine, cyano , Oxy-, Phenyl and Dimethyl-1. Radical f
    or R and R, if they are in the cis position, carbon with carbon /
    to which they are bound, form a ring of cyclopropane, cyclobutane, cyclopentene, or cyclohexane; or R is a carboxy radical; R, R MR is hydrogen,
    or if the compound of formula 1 contains a free acid or basic group
    pharmaceutically acceptable salts thereof with bases or acids, characterized in that the compound of formula
    H
    H, 1
    R and
    have the indicated interaction with the compound
    R3
    N
    ./
    ,eleven
    //
    AND
    where R and A have the indicated meanings,
     - fluorine or chlorine,
    in the presence of at least one equivalent of acid, and the desired product is isolated, or the compound of formula 1, in the form of free acid or free base, or in amphoteric form, if necessary translated in its pharmaceutically formulation, with the base salt or acid by reacting a compound of formula 1 in the form of a free acid, either in amphoteric form with a base containing a pharmaceutically acceptable cation, or by reacting a compound of formula 1. in the form of a free base, or in an amphoteric form with acid, soda zhaschey pharmaceutically acceptable anion.
    one
    The invention relates to a process for the preparation of new cephalosporin derivatives or their pharmaceutically acceptable salts with bases or acids, which have biologically active properties and can be used in medicine.
    A known method for producing cephalosporins not containing a k-acyl substituent on the 7-amino group, in particular, 7 benzylideneaminocephalosporins derived by reacting the corresponding 7-aminocephalosprin with benzaldehyde or its substituted prodew.
    7-benzylideneaminocephalosporins are used as products for the synthesis of 7-benzylidene-amino-7-methoxydephalosporins with biologically active properties ij.
    There is also known a method for producing (7p-amidinocephalosporins derivatives by reacting 7-aminocephalosporins with the correspondingly substituted thioamide 2. However, these compounds have low antibacterial activity. The purpose of the invention is to obtain new antibiotics of cephalosporin P5sha that do not contain an α-acyl substitution on the 7th group of cases in the 17th group). The aim is to achieve the production of cephalosporin derivatives of the general formula - Rj A {Vi "44 ,, -NV-Rl O R2. Where R is water genus or chlorine, methyl acetoxymethyl, 1-methyl-1H-tetrazol-5-ylthiomethyl, 1-carboxymethyl-1H-tetrazol-5-ylthiomethyl, 1- (2-dimethylamino) ethyl-1H-tetrazol-5-ylthiomethyl, 1-sulfomethyl -1H-tetrazol-5-ylthiomethyl, 1-isopropyl-1H-tetraZOL-5-ylthiomethyl, 1- (2,2,2-trifluoro) ethyl-Sh-tetrazole-Zgylthiomethyl, .1-phenyl-1H-tetrazole-5 -ylthiomethyl, 1- (2-methylthio) -ethyl-1H-tetrazol-5-ylthiomethyl, 1,3,4-thiadiazol-2-ylthiomethyl, 5-methyl-1,3,4-thiadiazol-2 -thiomethyl, 1 , 2,3-thiadiaz6l-5-ylty methyl, 1H-1,2,3-triazol-4-ylthiomethyl 5-trifluoromethyl-1H-1,2,4-triazole-3-ylthiomethyl, 4, b-dimethylpyrimide-2 - methylthiomethyl, 2-thiazols n-2-ylthiomethy of oxioxazol-2-ylthiomethyl, benzthiazo -2-ylthiomethyl, 2-carboxyphenylthiomethyl, (6-carboxymethyl-7-hydroxypyrrolo jji 2-y pyridazin-2-Sh1) thiomethyl,; methoxymethyl, methylhydroxymethylsyl, hydroxymethylmethyl, pyridazine-2-III , benzoyloxymethyl, acetylaminomethyl, carbamoyloxymethyl, 2-methylthio-1,3,4-tialiazol-5-ylthiomethyl, 2-mercapto-1,3, 4-thiadiazol-5-ylthiomethyl, 2-acetylamino-1, Zu 4-thiadiazole -5-ylthiomethyl, 5-methyl-1, 2,4-thia; Schiazol-2-ylthiomethyl, 2-sulfomethyl-1, 2,4-oxadiaeol-5-ylthiomethyl, 4-methyl-5- (3-carboxypropyl) thiazole -2-ylthiomethyl, 2H-2-methyl-1, 2,3-triazol-4-ylthiomethyl, 1H-1, 2,4-thiaz L-2-ylthiomethyl, 4,5-di | GIDro-b-hydroxy-4-metsh1-5-oxo-1, 2,4-triazin-3-ylthiomethyl, 2,5-dihydro-6-hydroxy-2- methyl-, 5-oxo-1,2,4-triazi-3-ylthiometsI, 1-OXYHYDROPYRID-2-ylthiomethyl, imidazo 4,5-7-pyrid-2-ylthiomethyl or imidazo 4,5-d | pyrimidine - 2-yl thiome; R is a carboxyl radical or a radical of the formula -COOCH OCOR where is methyl, ethyl or tert-butyl or R is a radium III of the formula -COOCHjCOCHj 1V R is hydrogen or OXY-, methyl methoxy, acetyl or 4-methoxybenzylradium; where H and R are the same or different — hydrogen or a cyano, hydroxy, carboxy, methyl, hydroxymethyl, 3-hydroxypropyl, ethoxycarbonyl, phenyl, aminomethyl, 2-hydroxypropyl, propyl, butyl or 3-aminopropyl radical, or R and R5 together with the carbon from which they are bonded, form a cyclohexene, benzene, naphthalene or dihydroacene naphthalene cyclic system, and the benzene ring is arbitrarily substituted by one or two for | salines selected from the group including fluorine, chlorine, hydroxy, amino, carboxy, nitro, methyl, methoxy, trifluorletyl, oxymethyl, aminomethyl, acetylammonium, azidomethyl, acetyl minomethyl, cyaimethyre, kar6a (4oylmethylradiphaph and the radical -OSONP2: -CH2N CH-N TcH) j -CHjNHCOCHjNH, -CH2NHCOCH () HH2 R -n are the same or different hydrogen, hydroxymethyl, gsinomethyl, carbamoyl, methoxycarbonyl, methyl, n-hexyl, phenoxymethyl, which will be suspended, it will be replaced by hydrogen. which can be substituted by one or two radicals, selected from the group including fluorine, chlorine, cyano, ksi-, phenyl and dimetilgi inoradikal; or 6c, if they are in the cis position, together with the carbon with which they are bonded, form a ring of cyclopropane, cyclobutane, cyclopeiten or cyclohexane; or K g t - carboxyrn shical,, R- - hydrogen. or if the compound of formula 1 contains the free acidic or basic group of their pharmaceutically acceptable salts with bases or acids, which consists in the fact that the compound of formula 1,; where R and R have the indicated meanings, they are reacted with a compound of the formula. where R and A have the indicated values n -fluorine or chlorine, in the presence of at least one equivalent of acid, and isolate the desired product, or compounds of formula 1, as free acid or free base, or in amphoteric form, if necessary t in its pharmaceutically acceptable salt with a base or acid by reacting a compound of formula 1 in the form of a free acid, or in an amphoteric form with a base containing a pharmaceutically acceptable cation, or by reacting a compound of formula 1 in the form of a free o Considerations, or amphoteric pho IU acid containing pharmaceutically acceptable anion. If the proposed method produces a compound of general formula 1 in the form of an acid addition salt, and an amphoteric compound is necessary, the compound of general formula 1 in the form of an acid addition salt is reacted with a low molecular weight epoxide, such as epoxy) opane. Preferably, salt with soybean, hydrobromic acid, phosphoric sulfuric acid, citric acid or maleic acid is obtained as the acid addition salt of the cephalosporin derivative. Preferably, an alkali metal salt, for example, an alkaline earth salt or potassium salt, i.e. a calcium or magnesium salt, or a salt with a primary, secondary or tertiary organically amine, such as triethylamine, procaine, dibenzylamine, or k, k-dibenzylethylenediamine. Cephalosporin derivatives are antibacterial agents, many of which have a wide spectrum of in vitro activity against both gram-positive and gram-negative pathogenic bacteria. The antibacterial spectrum and specific compounds can be determined by the usual control system. In tab. 1 shows the results of the biological activity of the three chemical subtypes (imidazoles, benzimidazoles and 2-imidazoles), tested on an in vitro control system, compared with the drug cefuroxime. Antibacterial activity is given as the minimum inhibitory concentration (MIC) determined by agar dilution method. The antibacterial properties of the proposed compounds are also confirmed in experiments on toes. The following compounds were injected under the skin into mice in two equal doses for one day, with each dose at least nine times the minimum effective dose that protects. 50% from bacterial infection (): 7- (imidazol-2-yl) amino-3- (1H-1-methyltetrazol-5-yl) -thiomethyl-3-em-4-carboxylic acid (100 mg / kg) ; 3-acetoxymethyl-7- (imidazol-2-yl) aminocef-3-em-4-carboxylic acid (100 mg / kg); 3-acetoxymethyl-7- (4-hydroxybenzylimidazol-2-yl) aminoceph-3-em-4-carboxylic acid (200 mg / kg); 3-acetoxymethyl-7-4-4- | d1 :: methylamino) phenylimidazol-2-yl aminoceph-3-em-4-carboxylic acid (100 mg / kg). No evidence of poisoning or side effects was found. In the same way, the compound 7-imidazol-2-yl (amino-3-) 2-methyl-1,3,4-thiadiazol-5-yl} thiomethylceph-3-em-4 carboxylic acid was administered71It was administered orally and under the skin of mice in an amount of 2 g / kg Again, no signs of poisoning or side effects were found. Cephalosporin derivatives obtained by the inventive method can be used in the form of pharmaceutical compositions in which cephalosporin derivatives are combined with non-toxic pharmaceutically acceptable excipients or carriers. The pharmaceutical composition may be administered orally, rectally or parenterally, for which it must be obtained in the form of tablets, capsules, aqueous or
    oily solutions, or suspensions, emulsions, dispersible powders, suppositories, or sterile aqueous or oily solutions, or suspensions used for infections.
    In addition to the cephalosporin derivatives of general formula 1, the pharmaceutical composition may also contain one or more known drugs selected from the group of other clinically acceptable antibacterial agents, for example, other β-lactams or aminoglycosides, lactamase inhibitors, for example clavulanic acid, renal tubular block agents such as probenicide, and inhibitors of metabolizing enzymes, such as inhibitor peptidase, such as Z-2-acylamino-3-substituted propenoates.
    A preferred pharmaceutical composition is one that is convenient for intravenous, subcutaneous, and intramuscular injection, for example, containing 1-10 weight,% of a cephalosporin derivative, or for oral administration in a dosage form, for example, in the form of tablets or capsules containing from 100 mg to 1 g derived cephalosporin.
    The pharmaceutical composition of the cephalosporin derivative is administered to a human to resist infections caused by bacteria intravenously, subcutaneously or intramuscularly in an amount of 0.5-50 g (preferably 0.5-10 g) 1-4 times per day.
    In the following examples, the characteristic NMR spectra are given in values relative to tetramethylsilane () as an internal standard, (s singlet, (1 doublet, t triplate, t multiplet, L :: shoulder). Temperatures are in degrees Celsius, and the boiling point of petroleum ether, unless otherwise specified, 47-61 0. The following abbreviations are used:
    TFA - trifluoroacetic cyblot;
    THF is tetrahydrofuran;
    NOLTS - acetic acid; .
    EtOAU - ethyl acetate;
    MeOH - methanol; DMF - dimethylformamide;
    DMCO - dimethyl sulfoxide; . ether - diethyl ether;
    HPLC - high pressure liquid chromatography.
    In the examples, the cephalosporin derivative is isolated in the form of a salt, g1mifion, an amphoteric compound, or an acid salt, e.g. HBr or. The most important salt that is selected depends on several factors, such as the basicity of the product, the conditions of the reaction, the treatment and purification, and the nature of the starting material (salt or free base). For example, in Examples 1-5, due to the pK of the benzimidazole ring, the added acid salt is usually trifluoroacetate, but it can also be a mixture of amphionic and trifluoroacetate. AT
    example b because of the pK imidazoline ring, the product can be isolated in the form of amphion trifluoroacetate of the same salt as the starting material (hydrobromide), or a mixture of two
    the three components listed above. Example.
    H AND
     B
    with.
    c
    HC1
    HN
    CEZ
    coaxial
    A solution of pivaloyloxymethyl 3-methyl-7-aminoceph-3-em-4-carboxylate toluene-p-sulfonate (3 g) in water (100 ml) is treated with an excess of KHCO. The mixture is extracted three times.
    5 with ethyl acetate and the combined extracts are washed with brine and concentrated. The residue (2 g) was dissolved in acetonitrile (75 ml) and 2-chloro-2-imidazoline hydrochloride was added.
    n) The mixture is stirred at
    0 for 5 h, filtered, and the filtrate is concentrated. The residue is recrystallized from isoprprol / ether to give pivaloyloxymethyl 3-methyl-7- (2-imidazolin-2-yl) aminocef-3-em-4-carboxylate hydrochloride (0.99 g) having an NMR spectrum in -1, 2 (s, 9H); 2.15 (s, 3N); 3.55 (dd, 2H); 3.8 (s,); 5.15 (d, IH); 5.4 (d, 1H);
    0 5.25 (dd, 2H).
    Example 2 To a stirred suspension, pivaloyloxymethyl-7-amino-3-methylceph-3-em-4-carboxylate .to5 luol-para-sulfonate in ethyl acetate was added sodium bicarbonate (0.336 g) in water. Separate the organic clasp, dry over MgSO4 and add one equivalent of HCl in diethyl ether. The mixture was evaporated to dryness, to which was then added dry DMF (3 ml) and 2-chlorobenzene / imidizol (1.218 g). The mixture was stirred for 24 hours and then evaporated to dryness.
    5 The residue is dissolved in CH2Cl2f, washed with water, the organic slurry is dried and concentrated, the product is purified by chromatography on silica gel using CH7C12 (MeOH)
    0 SLCA 98.5: 1: 0.5 (by volume) as eluent. The resulting oil is then purified by diisopropyl ether from precipitating a solution to give pivaloyloxymethyl-75 - (benzimidazole "g2-yl) amino-3-methylceph-3-em-4-carboxylate hydrochloride (14%), which has lines in the NMR spectrum in dfcDMCO: -, (s, 9H); 2.05 (З.НН) 3.65 (q, 2H); 4.25-4.8 {q, 2H); 4.75 (q, 2H); 6.9-7.4 (m, 2H). The process described is repeated using an equivalent amount of 2-chloro-5-nitrobenzimidazole instead of 2-chlorobenzimidazole at 50 s. The product is purified chromatographically at a reduced temperature on silica gel using (EtOAc) 70:30 (by volume) as eluent, solution are taken up in CHjClg and filtered off, then subjected to chromatography under reduced temperature using CEqCl-i (diethyl ether) MeOH 69: 30: 1 (by volume) as eluent to give pivaloyloxymethyl-7- (5-nitrobenzimidazol-2-yl) -3-methylceph-3 em -4-carboxylate (25%), having NMR spectrum in dgDMCO: -l, 15 (s, 9H); 2.05 (s, 3N); 3.5 (q, 2H) 5.25-5.8 (q, 2H); 5.8 (m, 2H); 7.3 8.0 (m, 3N); 8.5 (m, 1H). Example 3. - --S g) -CHN. I s co-NOSOs solution of acetoxime.til-7-amino-3 (2-methyl-1,3,4-thiazol-5-yl) -thiomethyl-cef-3-em 4-carboxylate (0.28 g) and hydrochloride 2 α-fluorimide ash (0.1 g) in dry DMF (1 ml) is heated at 60 ° C for 2 h. The reaction mixture is concentrated in vacuo and the residue is chromatographed on silica gel, eluting with CH2Cl2 (MeOH) 95: 5 (by volume). The purified compound is then treated with one equivalent of HC1 in MeOH. The hydrochloride is obtained by adding the resulting solution of dry ether. Acetoxymethyl-7- (imidazol-2-Il) hydrochloride but-3- (2-methyl-1,3,4-thiadiazol-5-yl-thiomethyl-3-em-4-carboxylate has the following peaks in 1H- Spectrum (KBr): 1780 (wide), 1740 (split), 1655 (narrow) and lines in the NMR spectrum in d DMCp + CF OOOD: - 2.15 (s, 3N); 2.7 (s, 3N ); 3.8 (brs, 2H); 5.3 and 5.8 (q, 2H); other resonances are masked with a solvent or poorly resolvable. The starting ester used in this process is prepared as follows. To a NaCl solution (3 g) in acetone (b ml) chloromethyl acetate (2.17 g) is added. The mixture is stirred for 1 hour at room temperature and a solution of 3- (2-methyl-1,3,4-thiazolol-5-yl) acetyl-amino-cef-3-em-4-sodium carboxylate (4.7 g) in DMSO (6 ml) is added. The mixture is heated for 5 hours, the acetone is evaporated and the residue is added to 200 ml of water. After trituration, a powder is obtained, which is filtered off and washed with ether. The wet product is purified by chromatography on silica gel eluting with CH2Cl2 (MeOH) 95: 5 (by volume ). The resulting acetoxymethyl ester is characterized by the following lines in the NMR spectrum in d DMCO + CD OD: -2.1 (s, 3N); 2.7 (s, 3N); 3.8 (m, 2H); 4.2 and 4.7 (q, 2H); 5.2 (d, 1H); 5.45 (h, 2H); 5.80 (d, IH): 5.9 (m, 2H); 9.3 (s, IH). Quinoline (1.93 g) is added to a solution of PCIf (2.08 g) in dry CH7C1.2 (12 ml). The resulting suspension is cooled to -15 ° C and the above acetoxymethyl ester (2.63 g ). The first mixture is warmed to room temperature and after one hour of stirring the resulting solution, it is added under nitrogen to a solution of 1,3-butane thiol (3 g) in cr. ml) cooled to. The mixture was stirred for 2 hours at room temperature and CH 2 Cl 2 (100 ml) was added again. The precipitate was filtered to give acetoxylmethyl-7-amino-3- (2-methyl-1, 3,4-thiadiazol-5-yl) -thiomethyl-cef-3-em-4-carboxylate hydrochloride (1.8 g) characterizing the following partial lines in the NMR spectrum in d DMCO-f tCD COOD: - 2.1 (s, 3N); 2.7 (s, 3N); 5.2 (brs, IH); 5.7 (brs, IH). When triethylamine is added to the chain of hydrochloride in a water / / CHgCl mixture until pH 8 is obtained, the free base is obtained. The organic phase is then separated and evaporated. Example 4. To a solution of toluene-sulfonic acid hydrate (54 mg) in dry DMF (1 ml), 2-fluoro-1-triphenylmethyl-imidazole (110 mg) is added and the solution is heated in a preheating bath to. after 5 min, 2-fluorimidazole-7-amino-3- (1,3,4-thiadiazol-2-yl) -thiomethyl-tsei-3-em-4-carboxylic acid is added to complete the formation. Heating is continued 2, 5 h, then add the next portion of fluorimidazole (50 mg), heating is continued for 30 wn, the mixture is cooled and evaporated at room temperature. Water (1C ml) and ethyl acetate (25 ml) are added to the residue, the mixture is filtered and the phases are separated. The end of the aqueous layer is triturated to 4 ml, filtered and subjected to high pressure preparative liquid chromatography on Whatman paper using a water / acetone mixture as eluant. Then it is washed with acetone and ether and 7- (imidazol-2-yl -) - amino-3- (2,3,4-thiadiazol-2-yl) -thiomethyl-cef-3-em-4-carboxylic acid (15 mg) is characterized by the following lines in the NMR spectrum in dg DMCO + +00 0000: - 3.52 (d, 1H); 3.79 (d, IH); 4.33 (d, IH); 4.6 (d, IH); 5.12 (d, IH); 5.58 (d, IH); 6.83 (s, 2H); 9.49 (s, IH). Similar to the described process using 4-carboxy-2-fluoro-1-triphenylmethyl-imidazole, 4-ethoxy carbonyl-2-fluoro-1-triphenylmethyl-imazole and 3-acetoxymethyl-7-aminoceph-3-it-4-carboxylic The following compounds are obtained as starting materials: S H H tv-ii i V. L СНСОСНЗ about t where R is СООСгН or 1. The product is purified using high pressure liquid chromography using eluent CMO sy water / MeOH / NOLTS 74: 25: 1 (by volume 2. The product is characterized by the following lines in the NMR spectrum in d DMCO: 1, 22 (t, ЗН); 2.03 (з.зн); 3.32-3, (q , 2H); 4.17 (q, 2H); 4.56-4, 93 (q, 2H); 5.14 (d, 1H); 5.67 (q, 1H) 7.01 (d, IH); 7.28 (s, IH). 3. The product is purified by liquid chromography under high pressure using a mixture of water / MeOH / NOAc 76.5:: 12.5: 1 (by volume). 4. The product has the following: NMR spectrum in d DMCO: -CDaCOgD: - 2.03 (&amp;,REL; 3751-3.6 (q / 2H); 4.72-5.0 (q, 2H); 5.16 (d, IH); 5.71 (d, IH); -7 , 24 (s, IH) The starting imidazole is obtained in the following manner. To a solution of 2-fluorimidazole (4.45 g) in CH2Cl2 (100 ml) and trimethylamine (7.93 ml) was added triphenyl methyl chloride (14.4 g 5 and stirred for 2.5 hours. The solution was washed with water and brine dried (MgSO4) / and then treated with decolorizing activated carbon, filtered and evaporated. The dry residue was triturated with ether and then with methanol to obtain 2-fluoro-1-triphenylmethyl-imidazole (fl3.6 g). M.p. 182-185 s. A solution of 2-fluoro-1-triphenyl-4-methyl-imidazole (3.28 g) in dry THF (33 ml) is treated under argon at -75 ° C with two equivalents of lithium tert-butylate (10 ml of 1.93 M solution in a pentane) . After stirring for 3 hours, DMF (1.5 ml) was added. The reaction mixture is kept for another 1 h at -75 ° C, then slowly heated to room temperature. The reaction is completed by diluting with ether, washing with 2NHC1 and then brine. The ether layer was concentrated under an argon stream to give 4-formyl-2-fluoro-1-triphenylmethyl-imidazole (2.2 g), m.p. 177179 ° C. A solution of 4-formyl-2-fluoro-1-triphenyl-methyl-imidazole (356 mg) in ethanol (5 ml) and (3 ml) is treated with silver nitrate (0.37 g) in water (0.5 ml), then 5 ml of potassium hydroxide solution (5 ml of 2.1 g of KOH in 35 ml of water) are added dropwise. The mixture is stirred at room temperature for 2 hours, filtered and the filtrate is extracted with ether. The aqueous layer was treated with concentrated HC1 to form an acidic medium and extracted with CHCl-j. The organic layer is dried over MgSO4, filtered, and the solvent is evaporated to give 4-carboxy-2-fluoro-1-triphenylmethyl-imidazole (261 mg) as a white dry substance, characterized by the following NMR spectrum lines in d DMCO: - 7.0 -7.68 (m, 1bH); 11.5-12.5 (Dg, 1H). A solution of 4-carboxy-2-fluoro-1-triphenylmethyl-imidazole (280 g) in THF (0.75 ml) is treated under argon 1,5-diazobicyclo-5,4,0-undec-5-ene (0,112 ml) then ethyl iodide (0.069 ml). The mixture was stirred at room temperature for 2 hours, then water was added and extracted with ether. The ether extract is dried over MgSO4 and evaporated to give .4-ethoxy-carbonyl-2-fluoro-1-triphenylmethyl-imidazole (185 mg) as a yellow foam, characterized by the following lines in the NMR spectrum in CDClj: - 1.38 (t , ZN)); 4.36 (q, 2H); 7.0-7.5 (m, 1bN). I Example 5. A suspension of anhydrous toluene-para-sulfonic acid (0.74 g) and 3-acetomethyl-7-amino-3-em-4-carboxylic acid (1.17 g) was mixed in dry DMF (175 ml) 15 min at room temperature with the formation of a partial solution. Another portion of 2-fluoro-imidazole (0.74 g) is then added and the mixture is stirred at 2 hours. The solvent is evaporated at room temperature, 2% (by volume) of aqueous HOAc (20 ml) is added to the residue and the mixture is extracted with ethyl acetate ( 20 ml). The aqueous layer is concentrated to 15 ml.
    filtered and the filtrate purified by preparative high pressure liquid chromatography on Whatman Partisil 10 using water / MeOH / HOAc (by volume) as eluent. Then the product is purified by rubbing; with acetone and. washing with acetone and ether to obtain 3-acetoxy-methyl-7- (imidaeol-2-yl) -aminoceph-3-em-4-carboxylic acid (0.42 g), in the form of the hydrated acetate / toluene-para-mixed salt sulphonate having So pl. 160 (decomposition) and characterized by the following lines in the NMR spectrum in DzO: 2.28 (s, 3N); 3.58 (d, 1H); 3.89 (d, IH) i 4.92 (d, 1H); 5.13 (d, IH); 5.42 (d, 1H); 5.70 (d, 1H); 7.08 (s, 2H).
    Similarly to the described process, using the corresponding 7-aminocephalosporin derivatives, the following ratios are obtained (see Table 2):
    1. The reaction is carried out for a period of 3 hours.
    2. The product is purified by isolation of the residue from the reaction mixture in distilled water, filtration and extraction with ethyl acetate. The aqueous layer is clarified with activated carbon, the pH is adjusted with an aqueous solution of NaOH and the volume is reduced to
    2 ml. Then the product is crystallized.
    3. The product has a mp. 203-220 ° (decomposition).
    4. The product is purified by preparative high pressure liquid chromatography on Whatman Partisil 10 using as eluate
    water / MeOH / NOLTS 70: 30: 1 (by volume).
    5. The product (dihydrate) is characterized by the following lines in the NMR spectrum in B O + TFA: - 3.3 (d, 1H); 3.64 (d, IH); 3.92 (d, 1H); 4.26 (d, 1H); 4.93 (s, IH); 5.20 (d, 1H); 6.56
    . (s, 2H); 6.75 (d. IH); 7.25 (d, IH).
    6. The product is purified by preparative HPLC on Whatman Partisil using a mixture of water / MeOH / NOAc 90: 10: 1 and crystallized upon treatment with acetone.
    7. The toluene-para-sulfonate salt is characterized by the following lines in the NMR spectrum in d DMCO-fCD-iCO D: 2, 32 (s, 3N); 3.64 (d, IH); 3.9
    (d, IH); 4.19 (d, IH); 4.46 (d, IH); 5.05 (s, 2H); 5.17 (d, IH); 5.57 (d., IH) -; 7.06 (s, 2H); 7.14 (d, 2H); 7.54 (d, 2H).
    Example 6. A solution of 0.18 g of pivaloyl-hydroxymethyl-g3-methyl-7-amino-cef-3-em-4-carboxylate (0.18 g) and 2-fluoro-imidazole hydrochloride (0.24 g) in DMF (1 ml) and acetonitrile (1 ml) are heated at 7 hours. After being ground, the residue is chromatographed over silica gel using CHjCi / MeOH 95: 5 (by volume) as eluent. The oil product is treated with one equivalent of HC1 in MeOH. The solution is evaporated, the residue is triturated with ether and filtered to give pivaloyl-hydroxy-methyl-7- (imidazol-2-yl) -amino-3-methylceph-3-em-4-carboxylate hydrochloride, which is characterized by the following lines in the NMR spectrum a d DMCO + Cb COOD: - 1.2 (s, 9H); 2.1 (s, 3N); 3.6 (m, 2H); 5.25 (d, IH); 5.7 (d, IH): 5.85 (m, 2H); 7.05 (s, 2H).
    Example 7. Analogously to Example 4, using the corresponding starting materials, the following compounds are obtained (see Table 3):
    1. Mixed toluene-para-sulfonate / acetate salt has the following
    characteristics in the NMR spectrum in dgDMCO: - 1.6-1.9 (m, 2H); 2.05 (s, 3N); 2.5 (t, 2H); 3.3-3.7 (t, H) 4.9 (q, 2H); 5.17 (d, 1H); 5.63 (q, IH); 6.61 (s, IH); 7.28 (q, 2H); 8, 8 (s, IH).
    2. High pressure liquid chromatography; solvent: water / MH / HOAc 70: 30: 1 (by volume).
    3. Mixed toluene-para-sulphate / acetate salt has in the NMR spectrum the following characteristic lines in d DMCO: - 1.6-1.9 (ii, 2H); 2.5
    (t, 2H); 3.3-3.7 (ha, UH); 3.95 (s, 3N); 4.34 (s, 2H); 5.08 (d, IH); 5.70 (q, IH); 6.58 (s, IH); 8.65 (s, IH).
    4. Mixed toluene-para-sulfonate / acetate salt has the following characteristic lines in the NMR spectrum in d DMCO: - 1.6-1.9 (m, 2H); 2.44
    (t, 2H); 3.42 (t, 2H); 3.59 (d, 4.04 (s, 2H); 5.08 (d, IH); 5.50 (a, IH); 6.57 (s, IH); 7.84 (s, IH) .
    The 2-fluoro-1-triphenylmethyl-4- (3-hydroxy) propyl imidazole used as the starting material was prepared as follows.
    To a solution of 2-fluoro-1-triphenylmethyl-imidazole (1.31 g) in THF (22 ml), lithium t-butoxide (4 ml of a 2 M solution in pentane) is added under argon. The red solution was stirred at -70 ° C for 2 hours after which copper-fO iodide, 78 g) was added. The resulting dark red solution was stirred for 1 hour and allyl bromide (1.8 ml was added. ). The mixture is heated to room temperature for 18 hours and then introduced into ether (150 ml). After that, the mixture is washed with a saturated aqueous solution of ammonium chloride (6 times 50 ml), then with brine 150 ml), treated with activated carbon and dried with MgSOj ,. The diluent is isolated to obtain 4-all-2-C top-1-triphenyl-methyl-imidazole as a slightly yellow solid with T, mp, 136-138 °. To a stirred solution of this derivative of allyl (3.68 g) in THF under argon at 5 ° C is added digiban (40 ml of 1m solution in THF). The mixture was stirred for 15 minutes, then at room temperature for another 16 hours. Water (20 ml) was added to the solution, then after 15 minutes 2N. NaOH (20 ml of aqueous solution) and 11202 (6 ml. 30 wt.% water solution). The mixture was kept for 2 hours at 50 ° C with vigorous stirring, then cooled, saturated with NaCl and the layer was separated. Aqueous layer of extractor, comfort with ether (three times 75 ml) and the combined extracts. washed with brine and dried with MgSO4. The solvent is evaporated and the residue is purified by chromatography on silica gel using CH2Cl2 / MeOH 40: 1 v / v as the eluent to give 2-fluoro-1-triphenylmethyl-4- (3-hydroxy) propyl-imidazole as a crystalline solid. in CDiOD, the following characteristic lines are shown in CDiOD: - 1.5-1.9 (m, 2n); 2.47 (t, 2H); 3.54 (t, 2H); 6.37 (s.IH) 7.0-7.5 (m, I5H). Example 8. Process wire as in Example 3 using 7-amino-3- (1,2, 3-thiadiazol-5-yl) -thiomethyl-cef-3-em-5-carboxylic acid as the starting material. The product is purified by high pressure liquid chromatography using 70: 30: 1 water (MeOH / HOAc) as eluent (v / v). 7- (imidazol-2-yl) -amino-3- (1,2,3-thiadiazol-5. -Yl) -thiomethyl-tsei-3-em-4-carboxylic acid is obtained, i.e. in the NMR spectrum in d DMCO + CD CO D lines 3.47 (d, IH); 3.71 (d, - 1H) f 4.36 (s, 2H); 5.13 (d, IH); 5.58 (d.IH) 6.81 (s, 2H): 8.88 (s, IH). Example 9. Analogously to Example 1, using the corresponding starting materials, the following compounds were obtained (see Table 4): B; 7 W n. R n I COOH 1, the gift spectrum of an amphion in L, 0: 2, 38 (s, 3N); 3.70 (d, IH); 4.11 (d, IH); 4.22 (s, l4H); 5.60 (d, IH 5.80 (d, IH). 2.HBr salt, T.PL. 160-164 c, Mr spectrum in CD-jOD: - 1.35 (a, ZN);, 13 (s, 3H); 3.28 (d, IH); 3.59 (d, IH); 4.2 (br, 3H); 5.12 (d, IH); 5.3 (d, IH 3. 3. NMR spectrum of hydrated oligomer TFA in dgDMCO: - 1.35 (s, 6n); 2.02 (s, 3N); 3.35 (s, 2H); 3.7 (br, 2H); 5.05 (d, IH); 5.38 (d, IH); 8.50-9.40 (m., 2H) 4. TFA salt dihydrate has a mp of 175-177 ° C (decomposition) NMR spectrum in dj DMSO: -2.07 (s, 3N); 3.30 (m, 2H); 3.50 (m, IH); 4.15 (m, IH); 5.15 (d, IH); 5.21 (t, IH); 5.51 Cd, IH); 7.40 (s, 5H); 9.0 (br, IH is reversible). 5. TFA salt, m.p. 110-115 c, NMR spectrum in d DMSO: -2.03 (s, 3H); 2.26 (s; 3H); 3.30 (d, IH); 3.62. (d, IH); 3.73 (m, 2H); 4.13 (m, 2H); 5.16 (d, IH); 5.51 (d, IH); 7.22 (m, IH). 6.HBr salt, m.p. 153-156C NMR spectrum in d pMCO:): - 2.06 (s, 3N): 2.97 (s, 3N); 3.49 (s, 2H); 3.64 (s,); 5.1 (d, IH); 5.44 (d, IH). 7. NMR spectrum of TFA salt in CD, jOD / CFUcOOD: - 2.10 (s, 3N); 3.44 (d, IH); 3.81 (d, IH); 3.81 (s, H); 4.86 (d, IH); 5.19 (d, IH); 5.20 (d, IH); 5.51 (d, IH). .eight. HBr salt. M.p. 167-170 ° C; NMR-88dtDMCO: - 1.52 (br, 8H); 2.08 (s, 3K); 3.38 (d, IH); 3.65 (d, IH); 3.92 (s, 2H); 5.12 (d, TH); 5.45 (d, IH). 9.TFA-salt, NMR spectrum in d DMCO: 2, 0 (s, 3N); 4.75 (d, IH); 5.0 fd, IH); 5.55 (m, IH); 5.2 (m, IH). Some resonances are masked by reversible plateau 1, 10.T.pl. 137-145 C (decomposition), NMR spectrum in d DMCO: - 2.02 (s, 3N); 3.2-4.5 (m, 9H); 5.1 (2d, 1H); 4.45 (m, IH); 6.8-7.5 (m, 5H). 11.T.pl. 172-180 ° C (decomposition), NMR spectrum in djDMCO: - 1.95 (s, ZNT; 2.7-4.5 (m, 7H): 5.0 (m, 1H); 5.5 (m , IH); 7.1 (m, lUH). 12. NMR spectrum in d DMCO: -2.0 (s, 3N); 2.9 (s, 6H); 3.0-3.8 (br Reversibly); 4.6-5.1 (br, ЗН); 5.2 (s, IH); 5.4-5.6 (g, IH); 6.7 (d, 2H); 7, 2 (d, 2H). 13. TFA SALT, YRM spectrum in dxDMCO / TFA: –2.05 (s, 3N); 3.45 (g, 2H); 3.6–4.0 (M, 2H ); 4.55 (M, IH); 5.05 (d, IH); 5.4 (dd, IH); 9.55 (d, IH). 14.T, square IBO ° C, 51MP- spectrum in dfiDMCO: - 2.05 h. 3N); 2.85 (s, 6H); 3.25-3.6 (m, 3N); 4.05 (t, IH); 4.95 (s, IH); 5.12 (d, IH); 5.4-5.55 (g, IH); - 6.7 (d, 2H); 7.2 (d, 2H); 8.4-8.8 (M, IH); 9.2 (m, IH); .9.75 (d, IH).
    15. NMR spectrum in diDMCO; 2.35 (s, 6H); 3.65 (m, 6H); 4.3 (dd, 2H); 5.1 (a, IH); 5.45 (d, 1H); 6.95
    (s, ta)
    16. NMR spectrum in DeDMCO: - 2.65 (s, 3N); 3.65 (s, ItH); 3.75 (dd, 2H)
    4.4 (dd, 2H); 5.1 (d, IH); 5.5 (dd, IH); 9.5 (d, IH).
    17. TP.P. 120-1500c (decomposition), NMR spectrum fi CD COjD: - 0.3 (m, IH) 0.9 (M, IH); 2.08 (s, 3N); 3.1-3.9 (m, UH); 5.10 (d, IH); 5.34 (d, IH).,
    18. The IR spectrum of the product (KBG) has the following absorption peaks of 1775 CM- (CO-NH); 1730 cm (COOH); 1650 cm (guanidine).
    19. NMR spectrum in CdCl + CD-jOD: 5, 10 (d, IH); 5.55 (d, IH); 3.0-4.6
    i (M, I.E).
    20. NMR spectrum in d DMCO + CD COOD: 3, 7 (s, UH); 3.85 (dd, 2H); 4.55 (dd, 2H); 5.2 (d, IH); 5.55 (d, IH); 7 / 2-7.7 (M, tH).
    21. NMR spectrum in CD-jOD: - 3.8
    (s, bn); 4.0 (s, 3H); 4.36 (s, 2H); 5.15 U, in); 5.4 (d, IH).
    22. NMR spectrum in dgDMCO: - 3.65 (s, UH); 3.6-4.0 (M, 2H); 4.55 (dd, 2H); 5.1 (d, IH) .; 5.5 (d, IH); 7.3-8.0 (M, l4H).
    23. NMR spectrum in d, DMCO + CD COOp: 3, 6-3.8 (M, 2H); 3.7 (s. ItH); 4.5 (dd, 2H); 5.15 (s, IH); 5.55 (s, IH) 7.7 (s, 5H).
    24.Т.ПЛ. 169-172 C, NMR spectrum in CDaOD (D20) d6DMCO: - 3.5 (d4, 2H)} 3.75 (s, + H); 3.95 (d-, IH); 4.4 (IH)
    5.05 (d, IH); 5.30 (d, IH); 7.358, 0 (M, kE).
    25.T.PL. 230 C (decomposition), NMR spectrum in d DMCO / CFjCOOD: - 2.0 (s, 3N); .3.6 (m, bN); 4.7 (d, 1H); 5.0 (d, IH); 5.1 (d, GN); 5.5 (: d, IH)
    26. Hydrochloride has an mp. lli C (decomposition), NMR spectrum in d DMCO / / CD COjD: - 2.1 (s, 3N): 3.54 (g, 2H) 3.2– 3.8 (m, 3N); 4.1 (t, 1H); 5.15 (d, IH); 5.2 (t, IH); 5.6 (d, IH); 7.4 (s, 5H).
    27. Hydrobromide (trifluoroacetate) has a TP. 172-175 ° С (decomposition), NMR spectrum in dgDMCO / CDjCOgD; - 2.05 (s, 3N); 3.55 Tg, 2H); 3.1-3.8 (m, IH); 4.2 (m, IH); 5.1 (d, 1H); 5.2 (m, IH); 5.9 (d, IH); 7.38-7.8 (m, 9H).
    28. The trifluoroacetate has an mp. 178-185s (decomposition), NMR spectrum in dgDMCO / CD-iOD: - 2.15 (s, 3N): 3.3-3.8. (m, 3N): 4.0-4.4 (m, 1H); 5.0-5, -7 (m, 3N); 7.8-8.0 (m, UH).
    29..HBr / TFA salt has m.p. 172-176 ° С (decomposition), 51МР spectrum in d / DMCO / CDiCOjD: - 2.05 (s, ЗН); 3.4 (m, 3N); 3.5 (g, 2H); 4.12 (m, IH); 5.1 (d, 1H); 5.15 (m, 1H); 5.5 (d, IH); 7.45 (m, UH).
    30. HBr / TFA salt has m.p. 178185 ° С (decomposition), ЯГ4Р-spectrum in d DMCO / CD, 2.05 (s, ЗН); 3.47 (g, 2H); 3.2-3.7 (m, IH); 4.2 (t, GN); 5.08 and 5.1 (2d, IH); 5.25-5.6 5 (m, 2H) i.5. ,, 4 .. (M UH). .
    31. The nuclear spectrum of TFA salt in d DMCO: 1, 9 (s); a 2.05 (s) (total GH); 3.2-3.6 (m, 3N); 4.1 (t, IH); 5.0 (M, IH); 5.1 (d, IH); 5.45 (d, IH); 0 6.7-7.4 (M, UH).
    32. NMR spectrum of TFA salt in d DMCO // CD CODE: -2.3 (s, 3H); 3.4-3.85 (M, 3H); 4.2 (t, IH): 5.05-5.20 (M, IH); 5.30 (d, IH); 5.07 (d, IH); 15 6.7-7.1 (M, 3H).
     33. Hydrated HBr / TFA salt has an mp. (decomposition), NMR spectrum in CO3S02S: - 0.88 (m, 3N); - 1.34 (m, YUN); 2.12 (s, 3N); 3.22 3.8 (g, 2H); 5.22 (d, 1 H); 5.55 (d, IH).
    34.TFA salt has m.p. 145147 ° G, NMR spectrum in CDCl-j / SVSOV: l2, 25 (s, 3N); 3.4-3.55 (m, 2H); 3.55-4.0 (m, 5H); 5.15 (d, 1H); 5.4 (d, IH).
    I ..- ..
    35.HBr / TFA. Salt has T. pl.
     (decomposition), NMR spectrum at 30 2.0 (s, 3N); 3.15-3.65 (g, 2H);
    3.75 (dd, IH); 4.05 (dd, IH); 5.15 {d, ih); 5.35 (d, IH).
    36. Mixed HBr / TFA salt has So pl. (decomposition) NMR spectrum
    35 in dfrDMCO: - 2.1 (s, 3N); 2.0-2.4 (M, UH); 3.25-3.72 (g, 2H); 4.2-4.6 (m, 2H); 5.15 (d, IH); 5.3 (d, IH);
    37.HBr / TFA salt has m.p. 170 ° C (decomposition) NMR spectrum in
    0 d6DMCO / D20: - 2.1 (s, 3N): 2.6 (m, 2H); 3.15-3.85 (g, 2H); 4.5-5.1 (m, 2H); 5.15 (d, IH); 5.35 (d, 1H); 5.8 (brd, IH); 6.05 (brd, IH).
    38. HBr / TFA salt has Tpl.155s hp: (decomposition), NMR spectrum in CDoCO D: 2.27 (s, 3N); 3.5 (Tr, 2H) 3.8
    (s, bn); 5.15 (s, 2H); 5.27 (d, 1H); 5.62 (d, IH).
    39. The HBr / TFA hemihydrate salt has an mp. 196-199c, NMR in
     CD COsD: - 2.11 (s, 3N); 3.42-3.7
    (g, 2H); 5.19 (d-, IH); 5.56 (d, 1H); 7.05 (m, yun).
    40. NMR spectrum of TFA amphion in CDaOD () DCl: - 3.80 (m, bN); 4.3
    5 (d, IH); 4.5 (d, IH); 5.2 (d, IH); 5.3 (s, 2H); 5.5 (d, IH).
    41. NMR spectrum of HBr / TFA salt in (i, DMCO (0.0,) TFA: –0.25 (m, IH); 0.80. (M, IH); 2.65 (s, 3H); 3 , 2-3.8 0 (M, UH); 4.25 and 4.5 (g, 2H); 5.1 (d, IH); 5.4 (d, IH), 42. HBr / TFA salt has mp (decomposition), NMR spectrum in d, DMCO / CD-jC0.2D: - 0.25 (m, IH); 0.8 (m, IH); 3.6 (m, UH) ; 3.9 (s, 3N); 4.25 (Zr, 2H); 5.05 (d, IH); 5.4 (a, IH), 43. NMR — Spectrum of TFA salt in d.DMCO + CD COOD: - 2.05 (s, 3, H); 3.2 -3.8 (m, ZN); 4.0 (t, IH); 4.9-5.1 (m, ZN); 5 , 45 (LP, 1H); 6.8 (d, 2H 7.2 (d, 2H). 44. NMR spectrum 2.TFA salts in 2.0 (s, 3N); 3.2-4.4 (m, bn); 4.44, 7 (m, IH); 5.15 (d, IH); 5.4 (d, IH). Example 10. Similarly, in Example 2, the following compounds are obtained (see Table. 5): i 1.TFA salt has mp 210-230 (decomposition), NMR spectrum in d / DMCO: 2.04 (s, 3N); 3.82 (m, HjO); 4.76 ( d, IH); 5.07 (d, IH); 5.28 (d, IH 5.84 (d, IH); 6.8-7.7 (M, UH); 2.nmr 6d DMCO / CP, OD: -2.02 (s, 3H); 2.43 (s, 3H); 3.40-4 , 0 (m, 2H); 4.0-6.0 (Dg, l + H); 6.70-7.7 (m, 3N). 3. NMR spectrum in d, DMCO: - 2.05 (s, 3N); 2.47 (s, 3N); 3.48, 3.72 (2d, 2H); 4.75, 5.05 (2d, 2H); 5.3 5.96 (2d, 2H); 7.05 (m, ЗН). 4. NMR spectrum in d DMCO / CD OD: 2, 04 (s, 3N); 2.35 (a, bn); 3.43, 3.73 (2d, 2H); 4.85, 5.15 (d, 2H); 5.30 (d, IH); (d, IH); 5.72 (d, IH 7.23 (s, 2H). 5. NMR spectrum in d DMSO: –2.12. (S, 3H); 3.7 (br, 2H); 4.77, 5 , 13 (2d, 2H); 5.37 (d, IH); 5.9 (br, I 6.60 (d, IH); 6.73 (d, IH); 7.05 (t, IH ); 6.90-7.80 (br, reversible); 10.15 (br, IH, reversible). 6. NMR spectrum in d DMCO: - 2.02 (s, 3N); 2.10 (s , ZN); 3.7 (br, 2H 4.7 5.05 (2d, .2H); 5.25 (d, IK /); 5.90 (br, IH); 6.90-7.35 (m, 3N) j 8.35-8.80 (m, IH); 9.97 (br, IH) 7. NMR spectrum in drDMCO: -2, Ob (s, 3H); 3.57 ( d, 2Hl; 4.73, 5.05 (2d, 2H); 5.27 (d, IH); 5.9 (m, IH 7.6 (M, 3H). 8. NMR spectrum in d DMCO: - 2.05 (s, 3H); 3.39, 3.74 (2d, 2H); 4.72; 5.07 (2d, 2H); 5.29 (d, IH); 5.95 (M, IH) ; 7.36 (M, 3H). 9.T.p.TFA SALT 185-187 C (dilution), NMR spectrum in D70./CD.,OD/T 2.3 (s, 3N); 3.24 , 3.60 (2d, 2H); 7.4 (M, UH). Other protons are masked by solvent re-effects. 10. The NMR spectrum of the TFA salt in 2.04 (s, 3N); 3.9 (m, 2H, Obm HjO); 5.75, 5.16 (2d, 2II); 7.03 (.-, H), mp 198-208 C. 11. T.pl. TFA salt 180-185 ° C: MR spectrum in CDCl / CDeOD: -2.04 (, 3N); 3.40, 3.04 (2d, 2H); 3.80 (s, 3N); 3.14 (d, IH); 5.44 (d, IH); 6.6-7.6 (m, 2H); 7.27 (d, IH). 12. NMR spectrum of TFA salt in CD OB: 2, 18 (s, 3N); 3.43, 3.56 (2d, 2P); 5.20, 5.65 (2d, 2H); 7.42 (s, 2H). 13. NMR spectrum of TFA salt in d DMCO: 2, 08 (s, 3N); 3.42-3.66 (2d, 2H); 5.27 (d, IH); 5.74 (d, IH); 6.52 (d, IH); 6.65 (d, IH); 6.97 (t, IH). 14.T.pl. TFA salt, (decomposition). The n.m.r.b d DMCOf 2.10 (s, 3H); 2.18 (s, 3n, 3,38, 3,67 (2d, 2H); 5,23 (d, IH); 5,80 (d, IH); 7,13 (M, 3H); 9, 15 (br, IH, reversible); 10.2 (s, IH, reversible). 15. Substituted benzimidazole has the formula 11 J – C 16. NMR spectrum of TFA salt in d DMCO: 2, 08 (s, 3 N) ; 3.35 (d, IH); 3.68 (d, IH); 5.25 (d, IH); 5.85 (d, IH); 7.20-8.15 (M, bN). 17. Substituted benzimidazole has the formula 18. NMR spectrum of TFA salt in d, DMCO; 2, 03 (s, 3N); 3.32 (s, H); 3.30 (d, IH); 3.60 (d , IH); (d, IH);; 5.22 5.80 (d, IH); 4.30-6, 70 (m, reversible) 7.15 (d, IH); 7.30 (s, IH) ; (t, IH); 7.87 (d, IH); 3.57 is reversible). 19. NMR TFA spectrum. salts in d DMCO: IH); 3.95 (s, .3.6 (d, IH); 3.9 (d,, - (s, 3H); 4.34 (M, 2H); 5, 25 (d, IH); IH ); 5.81 (d, IH); 6.90-7, 50 (m, H). T P, p n J about 20. NMR-spectrum TFA V salt in d dMCO: salt 2.69 (s, 3H ); 3.59 (dl, IH); 3.84 (d, TH); 4.23 (d, TH) I; 4.59 (d, IH); 5.25 (d, IH); 5 , 82 (d, .TH); 7.1-7.5 | (br, UH). 21.T.p. 181-182 ° C (decomposition); NMR spectrum in d DMSO: - 2.05 ( s, ZN); 3.5 (m, 2H); 3.7 (s, ZN); 5.2 (d, IH); 5.7 (d, IH); 7.2-7.7 (M , ItH.) 22. NMR spectrum in d DMSO: - 2.0 (s, 3H); 3.58 (s, + M, 3H “2H); 4.67 (d, IH); 4, 95 (d, IH); 5.2 (d, IH); 5.76 (d, IH); 6.95-7.42 (M,). D 23.T.pl. 180 C (decomposition)} NMR spectrum in djDMCO: - 2.05 (s, 3N); 3.42 (d, IH); 68 (d, IH); 4.70 (d, IH); 5.05 (d, IH); 5 , 18 (d, IH) 5.78 (d, IH); 6.4-7.1 (m, UH). 24.T.p. 1bO ° C / (decomposition); NMR spectrum in CDiOD containing 2 drops of d.DMCO: -2.00 (s, 3N); 3.70 (s, 3N); 3.5 (d, IH); 3.75 (d, 1 ); 4.8 (m, 2H); 5.15 (d, IH); 5.67 (d, IH); 5.31 (s, 2H); 6.66-7.66 (M, 8H) 25.T.PL .. 190 C (decomposition) NMR spectrum in CD OD / dfiDMCO: - 2.05 {s, .3H); 3.52 (d, IH); 3.80 (d, IH) 4, 87 (d .. ib) :. 5.16 (d, IH) ;. 5.28 (d, IH); 5.74 (d, IH); 6.6-7.3 (m, 3N), 26. NMR spectrum in d DMCO: –2.01 (s, 3N); 3.55 (m, 3N); 4.04 (m, 2H) 4.68 (s, IH); 5.01 (s, IH); 5.22 (s, IH); 5.85- (s,. Ih); 7-7.4 (m, ZN 27. NMR spectrum of TFA salt in 3.7 (m, 2H); 3.9 (s, ZN); 4.3 (s, 2H); 5.2 (d, IH) ; 5.75 (d, IH); 6.5-7.3 (m, 3N); 7.85 (d, IH). 28. NMR-spectrum of TFA salt in d of DMCO + -YU SrgO: - 2.05 (s, 3N); 3.3-3.8 (g, 2H); 4.6-5.05 (g, 2H); 5.24 (d, IH); 5.84 (d, IH); 7.3 (d, IH); 7.8 (M, 2H); 29. NMR spectrum of TFA salt in 2.04 (s, 3H); 3.6 (m, 2H); 4.72-5.1 ( g, 2H); 5.28-5.82 (g, 2H); 6.7-7.5 (M, 3H); 9.05 (M, IH). 30. NMR spectrum of TFA salt in 2, 1 (s, 3H); 3.7 (g, 2H); 4,, 12 (g, 2H); 5.34-5.90 (g, 2H); 7. (M, 3H) .-: , - .31. NMR spectrum of HB salt in dDMCO: 2, 04 (s, 3N); 3.38 (g, 2H); 4.52 (s, 2H); 4.71-5.03 (g , 2H); 5.25-5.8 (g, 2H); 6.9-7.25 (m, WZ). -F 32. NMR spectrum, 2.TFA salts in dgDMCO: - 2.06 ( -e, 3N) ;. 5.15-5.60 (g. 2H); 6.6-7.2 (m, 2H); two prrton resonances masked by a solvent. 33. NMR spectrum 2.TFA salt in dgDMCO: -2.02 (s, 2H); 3.6 (g, 2H); 4.75-5.05 (g. 2H); 5.25-5.78 (g. 2H) 6.5 -7.3 (m, ZN). 34. NMR spectrum 2.TFA salts in d, DMCO: - 2.1 (s, bn); 3.4 (m, 2H); 4.76-5.08 (g, 2H); 5.27-5.90 (g. 2H) 7.16 (s, 2H); 7.74 (s, 1H); 9.84 (s, IH). 35.YaIR spectrum of TFA salt in dxDMCO: 2.01 (s. 3N); 3.55 (m, 3N); 4.64 (m, 21); 4.68 and 5.01 (g, 2H); 5.22, 5.85 (g, 2H); 7.4-7., (M, 3N). 36. NMR spectrum of TFA salt in d DMCO:, 1 (s, 3N); 3.66 (m, 2H); 4.55 (v, 2H); 4.8-5.11 (g, 2H); 5.33-5.87 (g, 2H); 7.0-7.5 (m, ЗН). 37. NMR Spectrum .TFA salts in d DMCO-h / f .AJt 1 J.-I L. L. L. f tri. Ai 4. J4XI-I 1.88 (s, 34); 2.0 s, 3H); 3.48-3.6 (g, 2H); 4.3 (a, 2H); 4.7-5.05 (g, 2H); 5.23 (d, IH); 5.76. (D, IH); 6.90-7.4 (m, 3N). 38. NMR spectrum in d DMCO: - 2.02 (s, 3N); 3.54 (m, 2H); 4.17-4.4 (m, 2H); 4.7-5.05, (g, 2H); 4.90 (s, IH); 5.18 (d, IH); 5.82 (d, IH); 6.7-7.6 (M, 8H); 8.65 (m, IH). 39. NMR spectrum of TFA salt in d DMSO-SpasO D): - 2.05 (s, 3N); 3.0-4.0 (m, ItH); 3, bhm,); 4.37 (m, 2H); 4.75, 0 (g, H); 5.2 (d, IH); 5.78 (d, IH); 6.8-7.3. (M, 3N). 40. NMR spectrum of TFA Salts in d DMCO: 2, 03 (s, 3N); 3.42-3.67 (g, 2H); 4.01 (s, 2H); 4.71-5.01 (g, 2H); 5.22 (d, IH); 5.80 (d, 1H); 6.90-7.45 (m, 3N). 41. NMR spectrum of TFA salt in dgDMCO: 2, 07 (s, 3N); 3.39 (s, 2H); 3.0-4.0 (m, 2H); 4.7 (d, IH); 5.15 (d, IH); 5.24 (d. IH); 5, &amp; 6 (m, IH); 6.657, 45 (M, TH). 42. NMR spectrum of HB TFA salt in dgDMCO: - 1.72 (s, 8h); 2.09 (s, 3N); 3.18-4.0 (br, bn); 4.7-5.1 (br, UH); 5.2 (d, IH); 5.9 (d, IH); 6.9-7.5 (br, 3H); 8.5 (br, IH). 43. NMR spectrum of TFA salt in dr DMCO: 2, 10 (s, 3H); (d, IH); 3% 0 (d, IH); 3.72 (-s, 3H); 5.23 (d, IH); 5.67 (dIH); 7.18-7.58 (m, UH). Example 11. Proceed as in Example 3 and the following compounds were obtained (see Table 6): 1 V / li. 1.T.PL. 217-218 ° C; NMR spectrum. In drDMCO: - 2.00 (s, 3N); 3.30 (d, IH); EVIL (d, ih); 3.60 (d, 2H); 4.95, (d, IH); 5.55 (dd, IH); 6.40 (t, IH) 6.95-7.30 (M, 2H). , 2. NMR spectrum in (s, 3H); 3.25-3.55 (m, 2H); 5.10 (d, IH); 5.55 (d, IH). 3.T.PL. 220 C (decomposition); NMR spectrum in d DMCO: - 2.04 (s, bN); 3.44 (s, 2H); 5.04 (d, ib); 5.48 (d, IH); 6.42 (s, IH). 4.T.PL. 220 ° C (decomposition); NMR spectrum in d DMCO: - 2.0 (s, 3N); 4.65 (d, IH); 5.0 (d, IH); 5.05 (d, IH); 5.65 (dd, IH); 6.36 (t, IH); 7.05 (d, IH); 6.95 (br.s, IH). 5. NMR spectrum of TFA salt in d DMCO: 2, 075 (s, 3H); 3.48 (q, 2H): s, 2H); (d, IH); 5.5 (q, IH); 7.05 9.45 (d, IH). 6. NMR spectrum in dcDMCO: - 2.08 (s, 3H); 2.10. (s, 3H); 3.44 (dd, 2H); 6.10 (d, IH); 6.48 (d, TH); 6.55 D, J.U a, j.n; . (br s, IH). . 7, NMR spectrum at 3.10 (Z. HH 3.6-4.0 (m, IjH); 4.2 (m, 2H); 4.9 (m, 2H); 5.3-5, 5 (2d, 2H); 6.9 (s. 2H). 8. mp 140-145 ° C; NMR spectrum in dx-DMSO: -2.6 (s, 3N); 3.4 ( d, 1H); 3.8 (d, IH); 4.2 (d, IH); 4.5 (d.IH 5.1 (d, IH); 5.5 (dd, IH); 6.9 ( s, 2H); 9.2 (s, IH); 9.T. PL. 145-150 Cf NMR spectrum d, DMCO: -3.5 (d, IH); 3.8 (d, IH); 4.0 (M, 2H); 5.1 (d, IH); 5.5 (dd, IH); 7.05 (s, 2H); 7.2 (m, IH); 7.9 (s, IH ); 9.3 {d, IH). 10.T.P.P. 175-180Cj NMR spectrum in dgDMCO + CDaCOOD: - 3.5 (d, IH); 3.8 (d, IH); 4.0 (d, IH); 4.3 (d, IH); 5.2 (d, IH); 5.6 (d, IH); 7.0 (s, 2H); 7.2-8.0 ( m, 3N). 11. NMR spectrum in CDjOD + DgO; - 3.6 (d, IH); 3.9 {d, .IH); 4.3 (d, IH); 4.5 (d, IH); 5.25 (d, IH); 5.25 (s, 2H); 5.5 (dd, TH); 7.0 (s, 2H) 12.HD4R spectrum in d DHCO: - 2.1 (s, 3N); 2.15 (s, 3N) ;, 3.3 (d, 3H) 3.6 (d, IH); 5.1 (d, IH); 5.5 (m, IH); 6.7 (s, IH); 9.1 (m, IH). 13. NMR spectrum in dgDMCO: - 2.1 (s, 3H) ;. 2.7 (s, 3H); 3.6 (d, IH); 3.8 (d, IH); 4.2 (d, IH); 4.5 (d, IH); 5.2 (d, IH); 5.5 (dd, IH); 6.7 (s, IH); 9.2 (d, IH), 14. YANR spectrum in dgDMCO + CDaCO D 2.0 (s, 3H); 3.4-3.7 (m, 2H); 3.74 .1 (m, 2H); 5.2 (d, IH); 5.6 (d, IH); 6.7 (s, IH); 7.9 (s, IH); 15. NMR spectrum of TFA salt 2.05-2.1- (2s, 9H); 3.40-3.60 (2d, 2H); 5.1. (D, IH); 5, 4 (d, IH). 16. NMR spectrum of TFA salt in 2.06 (s, 3H); 2.28 (s, 3N); 3.333, 60 (2d, 2H); 5.18 (d, IH); 5.65 (d, IH); 7.2-7.6 (M, 5H); 8.2 (m, 1H 17.5 dar spectrum TFA / HB salts of B d, DMCO: –2.08 (s, 3N); 2.10 (s, 3H 3.30-3.60 (2d, 2H); 5.10 (d, IH); 5.48 (d, IH); 6.55 (s, IH). 18. NMR spectrum of 0.5 TFA salt in d DMSO: -2.0 (s, 3H) ; 3.4-3.65 (2d 2H); 4.3 (s, 2H); 4.75-5.05 (2d, 2H; 5.15 (d, -IH) -; 5.7 (m, IH); 6.8 (s, IH). 19. NMR spectrum of TFA salt in dgDMC 2.1 (s, 3H); 2.2 (s, 3H); 3.7 (s, 2H 4; 9 ( d, IH-); 5.2 (s, IH); 5.3 (d.IH 5.7 (M, IH); 6.8 (s, IH). 20. NMR spectrum of TFA salt in 1, 7 (m, UH); 2.0 (s, 3N); 2.4 ItH); 3.4-3.5 (M, 2H); 4.7 (d, 5.05 (d, IH); 5.1 (d, IH); 5, (d, IH). 21. NMR spectrum of TFA salt in d6DMCO + CD, COOD: -2.0 (s, 3H); 3.5-3, 6 (M 2H); 4.7 (d, IH); 5.0 (d, 1J); 5.2 (d, IH) I 5.7 (d, IH); 7-, 0 (s, 7, l- 7; 7 (M, 5H). 22. NMR spectrum of TFA salt in d-DMCO: 2 .04 (s, 6H); 2.67 (s, 3N); 3.68 (2d, 2H); 4, 26-4.56 (2d, 2H); 5.165, 48 (2d, 2H). 23. NMR spectrum of TFA salt in d DMCO: 2, 0 (sj 3H); 3.5-3.6 (q. 2H ); 4.7 (d, IH); 5.0 (d, IH); 5.2 (dj IH); 5.8 (d, IH); 7.3 (s, IB); 7.2-7.8 (M, 5H); 8.4-8.7 (M, IH 24.T.PL. 244Cj NMR spectrum in D O + TFAj - 3.03 (d, IH); 3.32 (d, IH); 3.58 (d. IH); 3.78 (d, IH); 4.95 (dj IH); 6.32 (s. 2H), one lactam proton is masked by the H20 resonance at 4.6-4.8. 25.T. Submarine hydrate (decomposition); ptg D4. .50 (d, 6H); 3.6 (d, IH); 3.83 (d, IH); 4.2 (s, 2H); 4.6-5.1 (m, IH); 5.48 (d, IH); 6.82 (s, 2H); one p-lactam proton disguised by HjO resonance. 26. NMR spectrum in D O + TFAs- 3.35 (d, IH); 3.60 (d, IH); 4.14 (8.2H); 4.98 (d, IH); 5.0 (q. 2H); 5.26 (d, IH); 6.64 (s, 2H). 27. NMR spectrum in d DMCO + CDgCOaD: 2.05 (s, 3H); 2.97 (t, 2H); 3.52 (d, IH); 3.78 (d, IH); 4.36 (bs, 2H); 4.51 (t, 2H); 5.09 (d, IH); 5.52 (d, IH); 6.82 (s, 2H. Example 12. Analogously to Example 1, the following compounds are obtained (see Table 7): R vUll t) CH 3 COOK 1. NMR spectrum of the trifluoroacetate salt in d HO + CD COOD; 2.1 (s, zn.); 3.25-3.7 (m, 3N); 4.1 (t, IH); 5.05, 3 (m, IH); 5.1 (d, IH); 5.45 (d, IH); 7.1-7.5 (m, UH). 2. NMR spectrum of trifluoroacetate salt in d / yDMSO + CD-jCOOD; 2.1 (s, 3N); 3.3-3.75 (m, -3H); 4.1 (t, IH); 5.15, 5 (m, 3H); 6.9-7.3 (m, UH). 3. Hydrobromic acid (trfluoroacetate salt) has a m.p. 190s (with decomposition) and the following indices of the NMR spectrum in d DMSO- “CD GOOD: 1.1 (d, bn); 2.08 (s, 3H); 3.32 (d, IH); 3.58 (d, IH); 4.1 (m, 2H); 5.08 (d, IH); 5.4 (d, IH). 4. Bromohydric acid (trifluoroacetate salt) containing 20% cis isomer has a stereochemistry corresponding to 1-threo-2,3-diaminobutane, m.p. (decomposition), NMR spectrum in d6DMSO + CD3.COOD: 1.2 (d, bn); 2.02 (s, 3N); 3.2-3.8 (m, H); 5.05 (d, IH); 5.36 (d, IH. 5. Hydrobromic acid (trifluoroacetate salt) has a stereochemistry corresponding to d-Tpeo-2,3-diaminobutane, mp, (decomposition), NMR spectrum in d DMSO + CDgCOO 1,2 (d, bn); 2.02 (s, 3N); 3.2-3.8 (m, UH); 5.05 (d, 1H); 5.35 (d, 1H 6. Hydrobromic acid (trifluoroacetate salt) has the following NMR spectrum in d DMSO + CDjCOOD: 1.22 (s, 12H); 2.1 (s, 3N); 3.35 (d, 1H); 3.63 (d, 1H 5 , 1 (d, .IH); 5.35 (d, IH). Example 13. Similarly to example 3, using the corresponding starting material, the following compounds are obtained (see Table 8) and Mr. R 1. It -n 1. NMR spectrum in dftDMSOi ЗЛ); 3.5 (d, IH); 3.8 (d, (d, IH); 4.3 (d, IH); 5.2 5.7 (m I H); 6.9 (s, 2H). 2. I 1P spectrum of the trifluoroacetate salt in dgDMSO: 3.2 (s, 3N); 3.5 Jm,,; 4.2 (s. 2H); 5 , 2 (d, IH); 5.5 (d, IH); 6.9 (d, 2H). 3. NMR spectrum of the trifluoroacetate salt in dgDMSO + CD3C02D: 3.6 (m, GN) 3.9 ( m, IH); 5.0 (d, IH); 5.3 (d, IH 5.4 (d, IH); 5.7 (d, IH); 7.0 (d, 2H); 7.4 - 8.1 (m, 5H). 4. NMR spectrum of the trifluoroacetate salt in d / DMSO + CDCOCO D 3.65 (s, 2H 5.1 (d, IH); 5.7 (d,.: IH); , 55 (t, .and); 7.0 (s, 2H). 5. NMR spectrum of the trifluoroacetate salt in d (, DMSO + CD.C02; D: 2.8 (s, 3N) 3.7 (d, IH); 3.8 (d, IH); 4.3 (d.lH 4.5 (d, IH); 5.2 (d, IH); 5.6 (d, IH); 7.0 (s, 2H). 6. NMR spectrum of the trifluoroacetate salt in d DMSO + CDOCOOD: 3.5 (d, IH) 3.6 (d, IH); 4.1 (d, IH); 4.2 (d, IH); 5.05 (d, IH); 5.6 (d, IH); 6.8 ( s, 2H.) 7. NMR spectrum of trifluoroacetate salt containing 20% of 8 isomers in 3.55 (d, IH); 3.75 d DMSO + CDjCOOD: (d, IH); 4.0 (d, IH) ; 4.5 (d, 1H) 5.25 (d, IH); 5.75 (d, IH); 7.0 is, 2H) 8. NMR-spectrum of the toluene-p-sulfonate salt in d DMSO ; 2.22 (s, 3H); 3.4–4.2 (ha, 6H); 5, OH (d, 1H); 5.52 (d, IH); 6.83 (s, IH); 7.0 (d, 2H) 7.5 (d, IH); 5.52 (d, IH); 6.83 (and IH); 7.0 (d, 2H); 7.5 (d, 2H ); 7.85 (s, IH). 9. NMR spectrum in dgDMSO- -CD | C02D: 3, .2-3.8 (m, l4H); 5.05 (d, IH); 5.55 (d, IH); 6.9 (s, 2H). 10. NMR spectrum in d DMSO + CD COOD 1.9 (g, 3H); 3, 3 (d, IH); 3.55 (d, IH); 3.9 (d, IH); 4.2 (d, IH); 5.0 d, IH); 6.8 (d, IH); 5.5 8.2 (s, 3H). 11. NMR spectrum in dgTjMSO: 2.05 (s ,, 3H); 3.58 (g, 2H); 3.85 (s, 2H); 4.7 (d, IH); 5.1 (d, IH); 5.17 d, IH); 5.68 (d, IH); 6.76 (s,. IH). 12. NMR spectrum in dgDMSO + TFA: 3.2 (d, IH); 3.5 (d, IH); 3.7 (s, 3H); 3.7 (d, IH); 4.1 (d, IH); 5.25 (d, IH); 5.51 (d, IH); 7.05 (s. 2H). 13. NMR spectrum in d DMSO-t-TFA: (s, 3N); 3.45-4.0 (m, 2H 2H); 5.25 (d, IH); 5.6 (d, 3.6 (s, 14. NMR spectrum in (d, IH); 2H); 3.8-4.1 (m, 2H); 5.05 5.45 (d, IH ); 6.8 (s, 6.8-8.1 (m, 3H). 15. NMR spectrum in D O + TFA: 3.95 (d, IH); 4.22 (d, IH) ji 5.0 (br, 2H) 5.52 (d, IH); 5.80 (d, IH); 7.2 (s, 2H); 9.0-9.3 (m, 2H). 16. NMR spectrum: B d DMSO / HOAc: 3.35-3.85 (m, 2H); 3.65-4.15 (m.2H) 4.0 (s, 2H); 5.2 (s, IH ); 5.35 (br, IH); 7.0 (s, 2H). 17. NMR spectrum in D O-npyridine:,.: 3.34 (d, IH); 3.6 (d, IH ); 4.25 (d, IH); 4.5 (d, IH); 5.26 (d, IH); 5.55 (d, IH); 6.65 (d, 2H). 18. NMR Spectrum B d DMSO + CD-COOD: 2.05 (m, 2H); 2.07 (s, 3H); 2.55 (t, 2H); 3.58 (g, 2H); 2H); 2.82 (t, 5.28 (d, IH); 5.9 (d. 4.89 (g, 2H); IH); 6.78 (s, Herewith: 1). The reaction is carried out in a mixture of methanol and chloroform 2), NMR spectrum of hydrochloride salt in dtDMSO + CD COOD: 2.65 (s, 3N); 3.75 (d, 2H); 4.4 (g, 2H); 5.25 (d, IH) ; 5.7 (d, IH); 7.0 (s, 2H); 7.6 (s, IH); 7, 75 (s,); 3). The reaction is carried out in the presence of potassium carbonate. four). NMR spectrum of a toluene-p-sulfonate salt containing 30% L-isomer 3H); 2.3 B d, DMSO + CDaCOOD: 1.25 (t, (s, 3H); 2.7 (s, 3H); 3.75 (m, 2H); 4.25 (s, IH); 4 55 (m, 2H); IH); 5.3 IH); 5.55 (m, IH) (s, 2H); 7.1 (s, 2H); Ih). Ih); 7.5 5). The product is purified by the -HPLC method. 6). NMR spectrum of the hydrochloride salt in TFA; 3.6 (d, IH); 3.9 (d, IH); 5.4 (s, IH); 5.6 (s, IH); 6.85 (s, 2H). 7). The reaction is carried out in a mixture of dimethylformamide with acetonitrile. eight.). NMR spectrum of hydrochloride salt in diDMSO: 3.8 (s, 2H); 4.35 (g, 2H); 5.15 fg, 2H); 7.08 (s, 2H); 9.11 (s, tn). 9). YNR spectrum of toluene-p-sulfo df. IGC-i sodium salt b. (S, 3N); 2.3 (s 34); 2.75-methyl-1,3,4-tnadiaeol-5-yl) thiome-tylceph-3-em-4-carboxylate, having the following NMR spectra in dj, DMSO-vGD COOD: 1.2 (t, 3H) j 2,1 „(s, ЗН); 2.25 (s, 3N); 2.75 (s, 3N) 4.2 (m,); 5.3 (m, 1H); S, 4. (m IH); 5.8 (s, 2H); 6.7 (d. 1H); 7D (d, IH); 7.5 (d, IH). Example 16. Similarly to Example 4, using the corresponding 2-fluoro-g1-triphenylmethyl-imidazl and 7-aminocephalosporin derivative, the following compounds are obtained as starting material (see Table 10). R n H ft. 1. Means for removing from the adsorbent by HPLC: water - methanol acetic acid 90: 10: 1 (by volume), 2. NMR spectrum in agDMSO + CDaCODD: 3.56 (q, 3N); 4.8 (q, 3N). 5.18 (d, IH); 5.58 (d, IH); 6.96 (s, IH 3. Means for extracting from the adsorbent by HPLC: water - methanol acetic acid 70t30: 1 (by weight per volume and per volume). 4. NMR spectrum in dgDMSO + CD3COOD: 3.46 (d , IH}; 3.74 (d, IH); 3.86 (d IH); 4.09 (s, 3H); 4.17 U, IH); 5.08 (d, IH); 5.5 (d, IH); 6.84 ("2H); 8.69 (s, IH); 5. Means for removing from the adsorbent by HPLC: water - methanol - acetic acid 75: 25: 1 (by volume). 6 .NMR spectrum in dDMSO + CDaCOjD: 1.07 (d, 3N); 2.46 (m, 2H); 3.66 (q, n) ;: 3.63 (s, 3N); 4.32 (ext, 2H 5.1 (d, -IH); 5.54 (d, IH); 6.64 (s, IH). 7. The initial fluorimide Eol is prepared as follows. In the large-scale production of 2-FTOR-4- (3-oxynyl pyranyl ) -1-triphenylmethylimidazole is separated isomeric isomeric 2-hydroxypropyl as a smaller product by chromatography on silica gel. Removed from the adsorbent with petroleum ether at t, kip, 60-80 0 mixed with ether: 50: 50-0: 100 (by volume). NMR spectrum in CDC1 ": 1.18 (d, 3N); 2.47 (m, 2H); 3.3 fbts.IH 4.0 {ffli IH); 6.27 (s, IH); 7.0-7.5 (m, I5H). 8. Means for extraction from the adsorbent by HPLC: water - metal acetic acid in a volume ratio of 60: 40: 1. 9. NMR spectrum in dgDMSO + CDjCOOD: 1.71 (m 2H); 2.18 (t, 2H); 2.24 (s, 3N); 2.7 (t, 3N); 3.44 (d, 1H); 3.73 (d, IH); 4.07 (d, IH); 4.47 (d, IH); 5.06 (d, IH); 5.54 (d, IH); 6.8 (s, 2H). 10, The starting material is prepared as follows. The reaction of 3-aletoxymethyl-7-aminoceph-3-em-4-carboxylic acid and 5- (3-carboxypropyl) -4-methyl-thiazole-2-thiol in pH 6.4 buffer in the presence of sodium bicarbonate gives 7-amino-3 - 5- (3-carboxypropyl) 4-methyl-thiazol-2-yl3 thiomethi-Zece-3-em-4-carboxylic acid, having the following NMR spectrum in d DMSO + fCDjCOOD: 1.71 (m, 2H); 2.17 (t, 2H); , 23 (s, 3N); 2.68 (t, 2H); 3.43 (d, IH); 3.74 (d, IH); 3.98 (d, IH); 4.44 (d, IH); 4.73 (d, IH); 4.93 (d, IH). 11. Solvent for HPLC: water methanol - acetic acid 55: 45: 1 (by volume). 12. YAIR-Spectrum in d DMSO + CD-, COOD: 0.9 (d, 3N); 1.1-1.8%, CH); 2.32 .5 (below NLO, 2H); 3.52 (d, 1H); 3.78 (d, IH); 4.34 (PGS 2H); 5.08 (d, IH); 5.56 (d, 1H); 6.58 (s, 1H). 13. The source material is obtained as follows. The reaction of 4-formyl-2-fluoro-1-triphenyl-methyl-imidazole and allyltriphenyl phosphonium bromide in methylene chloride in the presence of an aqueous solution of sodium hydroxide gives 4- (buta-1,4-dienyl) -2-fluoro-1- triphenylmethylimidazole. The resulting diene is hydrogenated over palladium on carbon in ethyl acetate at atmospheric pressure, which gives 4-butyl-2-fluoro-1-triphenylmethyl-imidazole, having the following NMR spectrum of 0.9 (t, 3N); 1.1-1.8 (m,); 2.42 (t, 2H); 6.2 (s, IH); 7.0-7.4 (m, 15H). 14, NMR spectrum in d DMSO + CDaCOOD: 3.46 (d, IH); 3773 (d. IH); 4.17 (s, 2H); 5.16 (d, IH); 5.55 (d, IH); 6.8 (m, 2H); 8.28 (dd, IH); 7.057, 69 (3H), 15, NMR spectrum in dgDMSO-fCD COOD: 2.13 (s, 3H); 3; 41 (d, IH); 3.73 (d, IH); 4.19 (d, IH); 4.44 (d, IH); 5.06 (d, IH); 5.54 (d, IH); 6.71 (s, 2H). The starting material was prepared in the following 5P (in an icicum manner. Reaction of 3-acetoxymethyl-7-aminoceph-3-em-7-carboxylic acid with 2-acetylL1 Mino-1,3,4-thiadiazole-5-thiol in a mixture of acetone with buffer pH 6.4 in the presence of sodium bicarbonate, gives 7-amino-3-2-acetylamino-1,3,4-thiadiazol-5-yl) thiomethyl-ceph-3-em-4-carboxylic acid, having the following NMR spectra in d DMSO-i- CD .HCOOD: 2.14 (s, 3N); 3/43 (d, IH); 3.73 (d, IH) 4.06 (d, IH); 4.4 (d, IH); 4.7 (d, IH); 4.91 {d, .ih).
    H V
    / Vra-T-f 1 J-l-f
    Table 1
     cooM 16. NMR spectrum in d DMSO + CDjCOOD: 2.13 (s, 3H); 2.41 (d, IH); 3.73 (d, IH); 4.19 (d, IH); 4.45 (d, IH)
    CH
    yv
    If-n
    iftjCooH
    Continued table. four
    27
    40
    Continuation of table 14
    Continued table. five
    ItTables
    n n
    HE
    2
    :: iEii
    H
    H H CH-i
    -
    t-r 1
    NN CHjS-f VOH
    SNS
    iCHiOCO /
    CH25 | I 1
     S $ SNS
    KK
     D
    "-H
    "M
    CHxjNHCOCn j
    CH-OCOCH2
    Continued table. 7
    Note
    H
    4 5 6
    H H CH,
    Table 8
    H H
     ;
    COOH
    3 4
    H H
    H H
    9
    10 11
    SNS
    Yv
    SNHZCH VoH Cho
    but
    CHjS
    SNS
    c "..
    W
    CH
    u-if
    CH, $ - U ll
    0 CHiSOsR
    CHjjOH CHjOCOCHg
    Lts
    CHtS-i-Lsnz
    ct
    Continued table. eight
    I
    Note
    12
    ..13
    14
    15
    H
    sixteen
    17 18
    CH CH CHyyHHg
    Table 9
    0R
    Coop Esop Well
    1,3,4
    5.6
    coon
    权利要求:
    Claims (1)
    [1]
    "The method of obtaining cephalosporin derivatives of General formula
    where in * is hydrogen or chlorine, methyl, acetoxymethyl, 1-methyl-1H-tetraeol-5-ylthiomethyl, 1-carboxymethyl-1H tetradeol-5-ylthiomethyl, 1- (2-dimethylamino) ethyl-1H-tetrazol-5-ylthiomethyl ,
    1-sulfomethyl-1H-tetraeol-5-ylthiomethyl, 1-isopropyl-1H-tetrazol-5gylthiomethyl, 1- (2,2,2-trifluoro) ethyl-1H-tetrazol-5-ylthiomethyl, 1-phenyl.- 1H-tetraeol-5-ylthiomethyl, 1- (2-methyl thio) -ethyl-1H-tetra-zol-5-ylthiomethyl, 1,3,4-thiadiazol-2-ylthiomethyl, 5-methyl-1,3,5 -thiadiaOl-2-ylthiomethyl, 1,2, 3-thiadiazol-5-ylthiomethyl, 1H-1,2, 3-triazol-4-ylthiomethyl, 5-trifluoromethyl-1H-1, 2,4-triazole-3-ylthiomethyl , 4, b-dimethylpyrimid-2- ^ yl'thiomethyl, 2-thiazolin-2-ylthiomethyl, beneoxaol-2-ylthiomethyl, benzthiazol-2-ylthiomethyl, 2-carboxyphenylthiomethyl, (6-carboxymethyl-7-hydroxypyrrolo [1,2] -b] pyridain-2-yl) thiomethyl, etoxymethyl, hydroxymethyl, azidomethyl, aminomethyl, benzoyloxymethyl, acetylaminomethyl, carbamoyloxymethyl, 2-methylthio-1,3,4-thiadiaeol-5-ylthiomethyl, 2-mercapto-1,3,4-thiadiazol-5-ylthiomethyl, 2-acetylamino- 1,3,4-thiadiazol-5-methylthiomethyl, 5-methyl-1,2,4-thiadiazol-2-thiomethyl, 2-sulfomethyl-1,2,4-oxadiaeol-5-ylthiomethyl, 4-methyl-5 - (3-carboxypropyl) -thiazol-2-ylthiomethyl, 2H-2-methyl-1,2,3-triazol-4-ylthiomethyl, 1H-1,2,3-triazol-2-yl-thiomethyl, 4, 5-dihydro-6-hydroxy-4-methyl-5-oxo-1,2,4-triaei n-3-methylthiomethyl, 2, dihydro-6-hydroxy-2-methyl-5-oxo-1,2,4 -triaen-3-ylthiomethyl, 1-hydroxy ; pyrid-2-ylthiomethyl, 'imidaeo [4,5-ъ] -pyrid-2-ylthiomethyl or imidaeo [4,5-a] pyrimidine - 2-yl thiomethyl;
    in 2 - carboxy radical or radical of Formula
    -COOCH g oson 10.
    where B * ° is methyl, ethyl or tert-butyl; B 2 is a radical of the formula —СООСН ^ СОСНз
    or
    I e
    m
    h
    Sp
    m
    SAZ
    -C00
    .0
    B 3 is hydrogen or hydroxy, methyl, methoxy, acetyl or 4-methoxybeneyl radical;
    1077573
    A is a radical of the formula
    where K 4 and K are the same or different - hydrogen or cyano ,. hydroxy-, carboxy-> methyl, hydroxymethyl,. 3-hydroxypropyl, ethoxycarbonyl, phenyl, aminomethyl, 2-hydroxypropyl, propyl, butyl or 3-aminopropyl radical, or K 4 and K 5 together with the carbon to which they are bonded, form a cyclohexene, benzene, naphthalene or dihydroacephaline naphthalene cyclic system, and benzene the ring is optionally substituted by one or two radicals selected from the group including fluorine, chlorine, hydroxy, amino, carboxy, nitro, methyl, methoxy, trifluoromethyl, hydroxymethyl ,. aminomethyl, acetylamino, azidomethyl, acetylaminomethyl, cyanomethyl, carbamoylmethyl radical and the radical of formulas
    - Osoin 2 ,
    -CH, H = CH-m2 ~ Gv ) 6
    -Si insosn kn ,
    - CH INSOSN (C 6 H 5 ) MN 2
    th <)
    In -K identical or different hydrogen, hydroxymethyl, aminomethyl, carbamoyl, methoxycarbonyl, methyl, n-hexyl, phenoxymethyl, which may be substituted by diphenylmethyl or phenyl, which may be substituted by one or two radicals selected from the group that includes fluorine, chlorine, cyano, hydroxy, phenyl and dimethylamino radical;
    or B 7 and B 8 , if they are in the cis position, together with carbon,
    to which they are associated, form a ring of cyclopropane, cyclobutane, cyclopentene or cyclohexane;
    or B 6 is a carboxy radical;
    B 7 , B 8 and K 4 - hydrogen,
    or if the compound of formula 1 contains a free acid or basic group
    their pharmaceutically acceptable salts with bases or acids, characterized in that the compound of the formula
    where B 1 and B 2 · have the indicated meanings,
    subjected to interaction with the compound of the formula
    I am 3
    where k'i A have the indicated meanings
    B 11 - fluorine or chlorine,
    in the presence of at least one equivalent of acid, and the target product, or the compound of formula 1, is isolated in the form of free acid, or free base, or in amphoteric form; if necessary, it is converted into its pharmaceutically intake ι salt with a base or acid by reacting a compound of the formula 1 in the form of the free acid, or in an amphoteric form with a base containing a pharmaceutically acceptable cation, or by reacting a compound of formula 1. in the form of a free base, or in an amphoteric form with an acid, contains boiling pharmaceutically acceptable anion.
    one
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1077573A3|1984-02-29|Process for preparing derivatives of cephalosporin or their pharmaceutically acceptable salts with bases or acids
    US4840944A|1989-06-20|Antibacterial beta-lactams, pharmaceuticals thereof and methods of using them
    KR840000797B1|1984-06-12|Process for preparing 6 -hydroxy alkyl-penicillanic acid derivatives
    US4623645A|1986-11-18|Substituted cephalosporin sulfoxides as anti-inflammatory and antidegenerative agents
    AU612990B2|1991-07-25|Antibiotic compounds
    GB1573004A|1980-08-13|Cephalosporin compounds
    SK16382000A3|2001-05-10|Carbapenem derivatives, utilization thereof and intermediate compounds of the same
    IE49046B1|1985-07-24|Carbamoyloxy penicillin and cephalosporin derivatives and the production of 3-cephems
    EP0055562B1|1986-02-12|Cephalosporin derivatives
    US4507239A|1985-03-26|Penicillin derivatives and process for preparation
    DE2521063A1|1975-11-27|PHENYLACETAMIDOCEPHALOSPORINE DERIVATIVES
    EP0700916B1|2001-06-20|Cephem compound, process for producing the same, and antibacterial containing the compound
    EP0630899A1|1994-12-28|Cephem compound, process for producing the same, and medicine containing the same
    DE2330307C2|1983-03-10|Cephalosporin compounds, their salts, processes for their preparation and medicaments containing these compounds
    IE45559B1|1982-09-22|Lactam antibiotics
    CA1150726A|1983-07-26|Cephalosporins, processes for the preparation andpharmaceuticals containing these compounds
    EP0050927B1|1985-03-27|The preparation of beta-lactam antibiotics
    EP0055099B1|1984-10-24|Penicillin derivatives
    EP0321186B1|1994-03-02|6-|penems
    EP0023093B1|1983-09-28|Penicillanic acid derivatives, their preparation and their pharmaceutical compositions with a penicillin or cephalosporin
    KR870000611B1|1987-03-25|Process for preparing cephalosporin derivatives
    GB2051046A|1981-01-14|Penicillanic acid derivatives
    SU1482532A3|1989-05-23|Method of producing cephem compounds or their physiologically or aharmaceutically acceptable salts
    EP0018155A2|1980-10-29|Novel cephalosporin compounds, a process for the preparation thereof, pharmaceutical compositions containing the same and the use thereof as a therapeutic agent against a microorganism
    DE2908033A1|1979-09-13|NEW CEPHALOSPORIN COMPOUNDS, PROCESS FOR MANUFACTURING THE SAME AND THERAPEUTIC PREPARATIONS CONTAINING SUCH ACTIVE SUBSTANCES
    同族专利:
    公开号 | 公开日
    NZ195731A|1984-04-27|
    ZW31280A1|1981-09-29|
    PL132587B1|1985-03-30|
    CA1175805A|1984-10-09|
    EP0031708B1|1984-06-13|
    JPH0320398B2|1991-03-19|
    ES502352A0|1982-05-01|
    ZA807710B|1981-11-25|
    ES8201167A1|1981-12-01|
    ES498157A0|1981-12-01|
    PT72265B|1981-11-05|
    ES8204438A1|1982-05-01|
    SU1031408A3|1983-07-23|
    GR71920B|1983-08-17|
    AU6513480A|1981-07-02|
    AU544374B2|1985-05-23|
    ZM11380A1|1982-10-21|
    DE3068273D1|1984-07-19|
    HU186289B|1985-07-29|
    EP0031708A2|1981-07-08|
    EP0031708A3|1982-02-24|
    NO803903L|1981-06-25|
    PL228757A1|1982-01-04|
    PL133508B1|1985-06-29|
    DD155520A5|1982-06-16|
    PH21662A|1988-01-13|
    FR2472574A1|1981-07-03|
    DK552480A|1981-06-25|
    FI803817L|1981-06-25|
    US4463173A|1984-07-31|
    PT72265A|1981-01-01|
    IL61775A|1984-08-31|
    CS226025B2|1984-03-19|
    PL232847A1|1982-03-29|
    YU324680A|1983-04-30|
    MW5380A1|1982-09-08|
    IL61775D0|1981-01-30|
    YU292682A|1983-06-30|
    AT7918T|1984-06-15|
    JPS56158787A|1981-12-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2430375A1|1973-06-26|1975-03-20|Leo Pharm Prod Ltd|Antibacterial 7-amino-delta-3-cephem-4-carboxylic acid derivs. - prepd. by reacting thio amide deriv. with a 7-amino-cephem-4-carboxylic acid deriv|
    US4358447A|1979-04-27|1982-11-09|Merck & Co., Inc.|7-N-Heterocyclyl cephalosporins|
    US4255424A|1979-04-27|1981-03-10|Merck & Co., Inc.|7-N-Heterocyclyl 1-oxa, 1-aza, and 1-carbadethiacephalosporins|
    EP0018595B1|1979-04-27|1986-08-20|Merck & Co. Inc.|7-n-heterocyclyl cephalosporins, a process for preparing and a pharmaceutical composition comprising the same|
    US4282219A|1979-08-01|1981-08-04|Merck & Co., Inc.|7-N-Heterocyclyl cephalosporins and antibiotic pharmaceutical compositions containing them|FR2496666A1|1980-12-22|1982-06-25|Ici Pharma|NOVEL CEPHALOSPORINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME|
    FR2496665A1|1980-12-23|1982-06-25|Ici Pharma|NOVEL PENICILLIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME|
    ZA824094B|1981-06-19|1983-07-27|Ici Plc|A process for the manufacture of cephalosporin derivative|
    EP0071370A3|1981-07-23|1984-05-16|Ici Pharma|Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them|
    US4504478A|1981-09-18|1985-03-12|Imperial Chemical Industries Plc|Cephalosporin-1-oxide derivatives|
    EP0082648A3|1981-12-21|1984-09-26|Imperial Chemical Industries Plc|Cephalosporin derivatives|
    JPH0375553B2|1982-12-16|1991-12-02|Asahi Chemical Ind|
    GR78718B|1983-01-31|1984-09-27|Ici Pharma|
    US4855420A|1983-06-03|1989-08-08|Ici Pharma|Cephalosporin derivatives|
    GB8316589D0|1983-06-17|1983-07-20|Ici Plc|Crystalline salts|
    US4547573A|1983-12-02|1985-10-15|Ici Pharma|Process for preparing cephalosporin derivatives|
    DE3687870T2|1985-09-09|1993-08-19|Otsuka Pharma Co Ltd|2-OXA-ISOCEPHEM COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF.|
    US4760140A|1986-10-20|1988-07-26|American Cyanamid Company|3-substituted-7-[5-substituted-2-thiazolyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid, diphenylmethyl esters|
    US6476220B2|2000-11-27|2002-11-05|Aurobindo Pharma Limited|Process for the preparation of furaca|
    US20030135041A1|2002-01-04|2003-07-17|Orchid Chemicals & Pharmaceuticals Limited, India|Synthesis of ceftiofur intermediate|
    US8394969B2|2008-09-26|2013-03-12|Merck Sharp & Dohme Corp.|Cyclic benzimidazole derivatives useful as anti-diabetic agents|
    WO2015042438A1|2013-09-19|2015-03-26|The Florida International Board Of Trustees Modesto A. Maidique Campus|Selective inhibition of bacterial topoisomerase i|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR7931616A|FR2472574A1|1979-12-24|1979-12-24|CEPHALOSPORINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME|
    [返回顶部]